STE · NYSE · Health Care Equipment
Health Care Equipment company based in Dublin, Ireland.
Last close, Oct 1, 2026
$209.34
Adjusted for splits and dividends
Last 12 months
-13.2%
S&P 500 +14.3% over the same dates
Market value
$20.4B
Last close × shares outstanding
Bets against the stock: 2.79M shares sold short (2.9% of shares outstanding), +14.1% vs the previous count, 4.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
1 sale
$957K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2026
$5.94B
+8.7% vs the year before
Net income, fiscal 2026
$782M
As reported in the annual filing
Shares outstanding
97.5M
As of Aug 4, 2026
In fiscal 2026 the company spent $236M buying back its own shares and $242M on dividends. Cash actually paid, from its cash-flow statement.
Congress tradeSits on House Ways and Means, Health3 different filers disclosed STE within 90 days. Disclosed 10 days after the transaction; reported as an official range, not an exact amount.
3 different filers disclosed STE within 90 days. Disclosed 15 days after the transaction; reported as an official range, not an exact amount.
4 different filers disclosed STE within 90 days. Disclosed 45 days after the transaction; reported as an official range, not an exact amount.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Stock since the trade -11.5% · S&P 500 -1.1% · to Oct 1Traded 7 days after resultsStock up 12% in the previous month
28K → 24K shares held−14% of their stake
A board member of Steris sold $957K of Steris shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
3 approvals or clearances and 5 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
8 certified in FY2026 Q3, vs 8 a year earlier. 8 positions in total, median offered wage $112K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 65.6% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 55.9%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 7.34M shares
STATE STREET CORPORATION
Schedule 13G: passive · filed May 12, 2026 · 5M shares
Vanguard Portfolio Management
Schedule 13G: passive · filed Apr 29, 2026 · 4.96M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $241.30 on Oct 1, 2025 to $209.34 on Oct 1, 2026 (-13.2%). Disclosed trades in the last 12 months: 0 insider purchases, 13 insider sales, 8 Congress purchases, 7 Congress sales.
Congress trade
Congress trade